Angiogenin-loaded fibrin/bone powder composite scaffold for vascularized bone regeneration
Source abstract
Abstract
Abstract Background Angiogenin (ANG) is a potent stimulator of angiogenesis. The aim of this study was to fabricate an ANG-loaded scaffold and to evaluate its angiogenic and osteogenic effects. In this study, we fabricated an ANG-loaded scaffold using bovine bone powder and fibrin glue. We then evaluated the structural, morphological, and mechanical properties of the scaffold and the in vitro release profile of ANG. Cell proliferation, viability, and adhesion were evaluated using endothelial cells in vitro , and angiogenesis and new bone formation were evaluated using a rabbit calvarial defect model in vivo . Results Micro-computed tomography imaging showed that the bone powder was uniformly distributed in the scaffold, and scanning electron microscopy showed that the bone powder was bridged by polymerized fibrin. The porosity and compressive strength of the scaffolds were ~60 % and ~0.9 MPa, respectively, and were not significantly altered by ANG loading. In vitro , at 7 days, approximately 0.4 μg and 1.3 μg of the ANG were released from the FB/ANG 0.5 and FB/ANG 2.0, respectively and sustained slow release was observed until 25 days. The released ANG stimulated cell proliferation and adherence and was not cytotoxic. Furthermore, in vivo implantation resulted in enhanced angiogenesis, and new bone formation depended on the amount of loaded ANG. Conclusions These studies demonstrate that a fibrin and bone powder scaffold loaded with ANG might be useful to promote bone regeneration by enhanced angiogenesis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Periodontal Regeneration and Treatments · Bone Tissue Engineering Materials · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Wonkwang Bone Regeneration Research Institute, Wonkwang University, Iksan 570-749, Korea.
Bonecell Biotech Inc., Dunsan-dong, Seo-gu, Daejeon 302-830, Korea.
Department of Herbal Crop Research, NIHHS, RDA, Eumseong 369-873, Korea.
Department of Dentistry, Oral and Maxillofacial, Wonkwang University, Iksan 570-749, Korea.
Funding
National Research Foundation of Korea (KR)
References (33)
Show source-provided references
1. Kuboki Y, Jin Q, Takita H. Geometry of carriers controlling phenotypic expression in BMP-induced osteogenesis and chondrogenesis. J Bone Joint Surg Am. 2001;83-A(Suppl 1):S105–15.
2. 10.1002/jbm.a.3323610.1002/jbm.a.33236 ↗
3. 10.1016/j.injury.2011.03.03510.1016/j.injury.2011.03.035 ↗
4. Ozturk BY, Inci I, Egri S, Ozturk AM, Yetkin H, Goktas G, et al. The treatment of segmental bone defects in rabbit tibiae with vascular endothelial growth factor (VEGF)-loaded gelatin/hydroxyapatite "cryogel" scaffold. J Pediatr Orthop B. 2013;23:767–74.
5. 10.1007/s12306-008-0064-110.1007/s12306-008-0064-1 ↗
6. 10.1021/bi00341a03010.1021/bi00341a030 ↗
7. 10.1038/sj.onc.120822310.1038/sj.onc.1208223 ↗
8. 10.1111/j.1600-0501.2004.00996.x10.1111/j.1600-0501.2004.00996.x ↗
9. Yao PP, Sung CY. Securinine metabolism. Zhonghua yi xue za zhi. 1973;4:229–35.
10. 10.1007/s00216-010-4455-410.1007/s00216-010-4455-4 ↗
11. 10.1002/dmr.561009051010.1002/dmr.5610090510 ↗
12. IIa B. Pharmacology of alkaloid securinine. Farmakol Toksikol. 1956;19:3–5.
13. 10.1111/1523-1747.ep1250007510.1111/1523-1747.ep12500075 ↗
14. 10.1093/ejechocard/jer11610.1093/ejechocard/jer116 ↗
15. 10.2515/therapie/201101810.2515/therapie/2011018 ↗
16. 10.1089/ten.teb.2008.052710.1089/ten.teb.2008.0527 ↗
17. 10.1016/S0142-9612(02)00374-510.1016/S0142-9612(02)00374-5 ↗
18. Stephan SJ, Tholpady SS, Gross B, Petrie-Aronin CE, Botchway EA, Nair LS, et al. Injectable tissue-engineered bone repair of a rat calvarial defect. Laryngoscope. 2010;120:895–901.10.1002/lary.20624 ↗
19. 10.1098/rsta.2004.146610.1098/rsta.2004.1466 ↗
20. 10.1016/j.biomaterials.2005.02.00210.1016/j.biomaterials.2005.02.002 ↗
21. 10.3390/ijms14061271410.3390/ijms140612714 ↗
22. 10.1111/j.1600-0501.2011.02164.x10.1111/j.1600-0501.2011.02164.x ↗
23. 10.1097/01.scs.0000231624.87640.5510.1097/01.scs.0000231624.87640.55 ↗
24. 10.1016/j.jbiosc.2014.03.01410.1016/j.jbiosc.2014.03.014 ↗
25. 10.1021/bm060223310.1021/bm0602233 ↗
26. 10.1016/j.biomaterials.2006.01.03310.1016/j.biomaterials.2006.01.033 ↗
27. 10.1016/j.jconrel.2005.03.02310.1016/j.jconrel.2005.03.023 ↗
28. 10.1006/bbrc.2001.556810.1006/bbrc.2001.5568 ↗
29. 10.1073/pnas.89.6.223210.1073/pnas.89.6.2232 ↗
30. 10.1359/jbmr.06012010.1359/jbmr.060120 ↗
31. [Peculiarities of hepatic experimental wound healing in rats treated with angiogenin]. Morfologiia. 2005;128:98–100.
32. King TV, Vallee BL. Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J Bone Joint Surg Br. 1991;73:587–90.10.1302/0301-620X.73B4.1712788 ↗
33. 10.1089/ten.tea.2007.000710.1089/ten.tea.2007.0007 ↗